HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line

Journal of Controlled Release

Volumn 54, Issue 2, 1998, Pages 223-233

  Minko, T ^a   Kopeckova P ^a,b   Pozharov, V ^a   Kopecek J ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Adriamycin; Doxorubicin; HPMA copolymer; MDR1 gene expression; Multidrug resistance; Ovarian carcinoma; Polymer drug conjugates

Indexed keywords

COPOLYMER; DOXORUBICIN; GLYCOPROTEIN P; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DNA, COMPLEMENTARY; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; METHACRYLATES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0345367901     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00009-1     Document Type: Article

References (39)

1. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Ríhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic Polymeric Drugs, US Pat. 5 037 883 (Aug. 6, 1991).
2. J. Kopeček, Biodegradation of Polymers for Biomedical Use, in: H. Benoit, P. Rempp (Eds.), IUPAC Macromolecules, Pergamon Press, Oxford, 1982, pp. 305-320.
3. Šťastný M., Říhová B., Strohalm J., Ulbrich K. Comparison of binding kinetics of antibody targeted N-(2-hydroxypropyl)methacrylamide (HPMA)-bound doxorubicin in vitro and in vivo. J. Control. Release. 42:1996;229-236.
4. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
5. Omelyanenko V.G., Kopečková P., Gentry C., Shiah J.-G., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the methods of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target. 3:1996;357-373.
6. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.-G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
7. Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Duncan R., Kopecek J. Biocompatibility of HPMA copolymers containing adriamycin. Biomaterials. 10:1989;335-342.
8. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., Ulbrich K., Strohalm J., Šubr V., Spreafico F., Grandi M., Ripamonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release. 19:1992;331-346.
9. J. Cassidy, P. Vasey, S.B. Kaye, R. Duncan, A phase 1 clinical trial of PK1: a novel drug targeting system in human cancers, 2nd Int. Symp. on Polymer Therapeutics, Kumamoto, Japan, 18-20 April, 1997, Proceedings, p. 18.
10. L.W. Seymour, D.R. Ferry, C. Boivin, P. Julyan, J. Doran, M. David, D. Anderson, C. Christodoulou, A.M. Young, D.J. Kerr, S. Hesslewood, Preliminary study of distribution of HPMA copolymers bearing doxorubicin and galactosamine, 8th Int. Symp. on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, 24-27 February, 1997, Abstracts, pp. 132-135.
11. Krinick N.L., Sun Y., Joyner D., Spikes J.D., Straight R.C., Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomat. Sci., Polym. Ed. 5:1994;303-324.
12. Fennelly D. Dose intensity in advanced ovarian cancer: have we answered the question? Clin. Cancer Res. 1:1995;575-582.
13. Ryser H.J.-P., Shen W.-C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl. Acad. Sci. USA. 75:1978;3867-3870.
14. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53:1993;4238-4242.
15. Alakhov V.Yu., Moskaleva E.Yu., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by Pluronic P85 block copolymer. Bioconjugate Chem. 7:1996;209-216.
16. Warren L., Jardillier J.-C., Malarska A., Akeli M.-G. Increased accumulation of drugs in mutlidrug resistant cells induced by liposomes. Cancer Res. 52:1992;3241-3245.
17. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44:1992;509-517.
18. V. Omelyanenko, P. Kopečková, C. Gentry, J. Kopeček, Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization and subcellular fate, J. Controlled Rel., (1998) in press.
19. Gottesman M.M. How cancer cells evade chemotharpy: sixteenth Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 53:1993;747-754.
20. Spoelstra E.C., Dekker H., Schuurhuis G.J., Broxterman H.J., Lankelman J. Pgp drug efflux pump involved in the mechanism of intrinsic drug resistance in various colon cancer cell lines. Biochem. Pharmacol. 41:1991;349-359.
21. Rejmanová P., Labský J., Kopeček J. Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol. Chem. 178:1977;2159-2168.
22. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growing/cell kill. J. Immunol. Methods. 119:1989;203-210.
23. F.H. Johnson, H. Eyring, B.J. Stover, The Theory of Rate Processes in Biology and Medicine, Wiley, New York, 1974.
24. R.N. Barnett, Clinical Laboratory Statistics, Little, Brown and Co., Boston, MA, 1979.
25. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L., Gazdar A.F., Willman C.L., Griffith B., Von Hoff D.D., Roninson I.B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 87:1990;7160-7164.
26. Chen C., Clark D., Ueda K., Pastan I., Gottesman M.M., Roninson I.B. Genomic organization of the human multidrug resistance (MDR1) gene and origin of Pgps. J. Biol. Chem. 265:1990;506-514.
27. Komarov P.G., Shtil A.A., Buckingham L.E., Blasubramanian M., Piraner O., Emmanuele R.M., Roninson I.B., Coon J.S. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acids diesters, novel inhibitors of P-glycoprotein function. Int. J. Cancer. 68:1996;245-250.
28. Lidor Y.J., O'Briant K.C., Xu F.J., Hamilton T.C., Ozols R.F., Bats R.C. Jr. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J. Clin. Invest. 92:1993;2440-2447.
29. Bell D.K., Gerlach J.H., Kartner N., Buick R.N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol. 3:1985;311-315.
30. Duncan R., Kopečková-Rejmanová P., Strohalm J., Hume I., Cable H.C., Pohl J., Lloyd J.B., Kopeček J. Anticancer agents coupled to N-(hydroxypropyl)meth-acrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer. 55:1987;165-174.
31. Maeda H., Seymour L.M., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-362.
32. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(hydroxypropyl)methacrylamide copolymers. Biomaterials. 6:1985;45-48.
33. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OVTL16 antibody conjugates. 2. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer. 75:1998;600-608.
34. AD cells and its relation to cellular drug localization. Biochim. Biophys. Acta. 1093:1991;147-151.
35. Chaudhary P.M., Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85:1993;632-639.
36. Muller C., Goubin F., Ferrandis E., Cornil-Schwartz I., Bailly J.D., Bordier C. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol. Pharmacol. 47:1995;51-56.
37. Hu X.F., Slater A., Wall D.M., Kantharidis P., Parkin J.D., Cowman A., Zalcberg J.R. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br. J. Cancer. 71:1995;931-936.
38. 2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem. 271:1996;30950-30955.
39. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Develop. Biol. 11:1995;549-599.